BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)
Status:
Enrolling by invitation
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm, multi-center study, assessing efficacy and safety of
BI-754091 in combination with afatinib as treatment in patients with advanced or metastatic
ESCC refractory to at least 1 line of systemic treatment (including chemotherapy or radiation
therapy).
Phase:
Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital China Medical University Hospital Kaohsiung Medical University Chung-Ho Memorial Hospital National Cheng-Kung University Hospital Taipei Veterans General Hospital, Taiwan